DUBLIN, July 8, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/24nt73/global) has announced the addition of the "Global Alzheimer's Drugs Market 2014-2018" report to their offering.
Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain.
AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.
This report covers the present scenario and the growth prospects of the Global Alzheimer's Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer's disease.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer's Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
The Global Alzheimer's Disease Drugs Market 2014-2018 report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer's Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Disease Overview
07. Alzheimer's Disease
08. Market Landscape
09. Market Segmentation by MOA
10. Market Assessment of Top Drugs
11. Competitive Assessment of Top Drugs
12. Focus on Alzheimer's Research
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
22. Future Vendors Expected To Tap the Market
23. Key Vendor Analysis
24. Other Reports in this Series
- Adamas Pharmaceuticals Inc.
- Archer Pharmaceuticals Inc.
- Eisai Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- FORUM Pharmaceuticals Inc.
- Forest Laboratories Inc.
- H. Lundbeck A/S
- Janssen Pharmaceuticals Inc.
- Novartis AG
- Merck & Co.
- MorphoSys AG
- Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical
- Takeda Pharmaceutical Co.
- TauRx Pharmaceuticals Ltd.
- Zinfandel Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/24nt73/global
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets